|This article relies too much on references to primary sources. (April 2007)|
The CytRx oncology pipeline includes three programs in clinical development: bafetinib, tamibarotene and INNO-206. The company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), a pharmacokinetic clinical trial in brain cancer and the PROACT Phase 2 clinical trial in advanced prostate cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx is conducting a safety trial with plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for soft-tissue sarcomas and pancreatic cancer. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung carcinoma and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL).
CytRx is currently working with the FDA guidance in 8 clinical trials involving their lead drug aldoxorubicin (formerly INNO 206). Aldoxorubicin is a derivation of doxorubicin the popular chemotherapeutic agent known as "red death".Doxorubicin Aldoxorubicin is currently working with Eli Lilly and Bristol Myers Squibb in combined efforts to measure the success of aldoxorubicin. Clinical trial information can be researched and found at the government web site clinical trials dot com (as noted below):
1)Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors 2)Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors 3)Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma 4)Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma 5)Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors 6)A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma 7)Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer 8)Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
Aldoxorubicin (formlerly INNO-206) is a tumor-targeted doxorubicin conjugate. Specifically, it is the (6-Maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin (DOXO) attached to an acid sensitive linker (EMCH). We believe this novel agent has attributes that improve on native doxorubicin including reduction of adverse events, improvement in efficacy and the ability to reach the tumor more quickly. CytRx holds the exclusive worldwide rights to aldoxorubicin.
The proposed mechanism of action is as follows:
- After administration, aldoxorubicin rapidly binds endogenous circulating albumin through the EMCH linker
- Circulating albumin preferentially accumulates in tumors, bypassing uptake by other non-specific sites including heart, bone marrow and gastrointestinal tract
- Once albumin-bound aldoxorubicin reaches the tumor, the acidic environment of the tumor causes cleavage of the acid sensitive linker
- Free doxorubicin is released at the site of the tumor
CytRx holds the exclusive worldwide rights to aldoxorubicin.http://www.cytrx.com/aldoxorubicin
Arimoclomol (INN, originally codenamed BRX-220) is an experimental drug developed by CytRx. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
Steven Arthur Kriegsman is the President and CEO.
In 2014 CytRx was involved in a stock promotion scheme, paying DreamTeamGroup US$65,000 to write at least 13 articles that appeared on Seeking Alpha, Forbes.com, Motley Fool, and Cheat Sheet. The articles carried no conflict of interest disclosure, and were reviewed and edited by CytRx management. The stock price doubled following the articles. The articles and author profile pages (including pseudonyms) were removed after investigation by CNNMoney. A class action lawsuit has been filed against CytRx.
The events leading to CytRx lawsuits were revealed by a Seeking Alpha author named Richard Pearson who was shorting the CytRx company stock and the "short attack" was revealed by another Seeking Alpha author PhD. who wrote about the science of aldoxorubicin and revealed the motives behind Richard Pearson's article to short the company's stock. The second Seeking Alpha article pointed to a financial motive for the negative article and that the author Richard Pearson took a short position in CytRx company stock 3 days before he published his article about CytRx. http://seekingalpha.com/instablog/4519051-nir-etkovitz/2756043-behind-the-short-are-investors-of-cytrx-that-shallow
Despite the controversy on how CytRx was handling their marketing and information release of their lead drug aldoxorubicin other companies like Bristol Myers Squibb and Eli Lilly have stepped into the clinical arena with interest and have combination clinical trials ongoing with their respective drugs as noted in the clinical trials government link.
- "At financial news sites, stock promoters make inroads - The Term Sheet: Fortune's deals blogTerm Sheet". CNN. Retrieved 20 April 2014.
- "CytRx Corporation (CYTR) news: Behind The Scenes With Dream Team, CytRx And Galena - Seeking Alpha". Seeking Alpha. Retrieved 20 April 2014.
- "Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors of the May 13, 2014 Deadline to File for Lead Plaintiff in the Securities Fraud Class Action Against CytRx Corporation -- CYTR - MarketWatch". MarketWatch. Retrieved 20 April 2014.